Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial-Reference-Cited by-同舟云学术

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Published:2017-01 Issue:10066 Volume:389 Page:255-265
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Rittmeyer Achim,Barlesi Fabrice,Waterkamp Daniel,Park Keunchil,Ciardiello Fortunato,von Pawel Joachim,Gadgeel Shirish M,Hida Toyoaki,Kowalski Dariusz M,Dols Manuel Cobo,Cortinovis Diego L,Leach Joseph,Polikoff Jonathan,Barrios Carlos,Kabbinavar Fairooz,Frontera Osvaldo Arén,De Marinis Filippo,Turna Hande,Lee Jong-Seok,Ballinger Marcus,Kowanetz Marcin,He Pei,Chen Daniel S,Sandler Alan,Gandara David R

Publisher

Elsevier BV

Subject

General Medicine

Reference21 articles.

1. Considerations for second-line therapy of non-small cell lung cancer;Stinchcombe;Oncologist,2008

2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

3. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

5. Inhibitory B7-family molecules in the tumour microenvironment;Zou;Nat Rev Immunol,2008

Cited by 3902 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Treatment - Radiation Therapy;International Encyclopedia of Public Health;2025

2. Ovarian angiosarcoma: A systematic review of literature and survival analysis;Annals of Diagnostic Pathology;2024-12

3. Sleep disturbance as a poor prognostic predictor in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A prospective study;Journal of Psychosomatic Research;2024-11

4. Lung cancer mortality trends and disparities: A cross-sectional analysis 1999–2020;Cancer Epidemiology;2024-10

5. Predicting resistance and pseudoprogression: are minimalistic immunoediting mathematical models capable of forecasting checkpoint inhibitor treatment outcomes in lung cancer?;Mathematical Biosciences;2024-10